Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
Regular Articles
Perturbed Calcineurin-NFAT Signaling Is Associated with the Development of Alzheimer’s Disease
Masashi AsaiAimi KinjoShoko KimuraRyotaro MoriTakashi KawakuboKeiro ShirotaniSosuke YagishitaKei MaruyamaNobuhisa Iwata
Author information
JOURNALS FREE ACCESS FULL-TEXT HTML

2016 Volume 39 Issue 10 Pages 1646-1652

Details
Abstract

Down syndrome (DS), the most common genetic disorder, is caused by trisomy 21. DS is accompanied by heart defects, hearing and vision problems, obesity, leukemia, and other conditions, including Alzheimer’s disease (AD). In comparison, most cancers are rare in people with DS. Overexpression of dual specificity tyrosine-phosphorylation-regulated kinase 1A and a regulator of calcineurin 1 located on chromosome 21 leads to excessive suppression of the calcineurin-nuclear factor of activated T cells (NFAT) signaling pathway, resulting in reduced expression of a critical angiogenic factor. However, it is unclear whether the calcineurin-NFAT signaling pathway is involved in AD pathology in DS patients. Here, we investigated the association between the calcineurin-NFAT signaling pathway and AD using neuronal cells. Short-term pharmacological stimulation decreased gene expression of tau and neprilysin, and long-term inhibition of the signaling pathway decreased that of amyloid precursor protein. Moreover, a calcineurin inhibitor, cyclosporine A, also decreased neprilysin activity, leading to increases in amyloid-β peptide levels. Taken together, our results suggest that a dysregulation in calcineurin-NFAT signaling may contribute to the early onset of AD in people with DS.

Graphical Abstract Fullsize Image
Information related to the author
© 2016 The Pharmaceutical Society of Japan
Previous article Next article
feedback
Top